Month: September 2022

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic...

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan

“Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit“Effect of nasal anti-CD3 (foralumab) in...

Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

- Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury - - Xequel Launches New...

WIMI Hologram Academy: The Application of Virtual Reality technology in pulmonary function rehabilitation in COVID-19 patients

HONG KONG, Sept. 27, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,...

Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD

ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working...

error: Content is protected !!